GlobeNewswire by notified

Alm. Brand Group afholder kapitalmarkedsmøde og offentliggør nye finansielle mål for 2025

Del

Selskabsmeddelelse nr. 22/2022

Alm. Brand Group afholder kapitalmarkedsmøde og offentliggør nye finansielle mål for 2025

Alm. Brand Group afholder i dag kapitalmarkedsmøde (Capital Markets Update) og præsenterer i den forbindelse forretningsplaner og nye finansielle mål for 2025.

Alm. Brand Group lancerede i begyndelsen af 2020 finansielle mål for 2022 og er i de seneste knap tre år lykkes med at forbedre værdiskabelsen og har dermed enten indfriet disse mål eller gennem frasalg af aktiviteter realiseret et væsentligt værdipotentiale.

Nye finansielle mål

Med overtagelsen af Codan er der skabt en ny og større forretning, og for den samlede Koncern er der fastlast et mål om at realisere et forsikringsteknisk resultat på 2,1 mia. kr. inklusive afløbsresultat og at reducere Combined Ratio til 84, heri indeholdt en reduktion af omkostningsprocenten til 16.

Alm. Brand Group introducerer endvidere et nyt rentabilitetsmål defineret som afkastet på den materielle egenkapital (Return on Tangible Equity) på mere end 50% i 2025.

Alle finansielle mål er understøttet af realiseringen af synergier som følge af overtagelsen af Codan på samlet 600 mio. kr. frem mod 2025.

Administrerende direktør i Alm. Brand Group, Rasmus Werner Nielsen udtaler:

”Med sammenlægningen af Alm. Brand og Codan har vi skabt vi en ny stærk dansk forsikringskoncern og et solidt fundament for udvikling. Vores mål er at fordoble vores tekniske resultat, væsentligt forbedre vores combined ratio og sikre de synergier, vi har lovet. Vores nye ambitiøse finansielle mål understøttes af et skarpt fokus på lønsom vækst, lavere omkostninger samt en succesfuld sammenlægning. For at indfri vores høje ambitioner vil vi med vores samlede styrker gøre det enkelt og endnu mere relevant at være kunde hos os, udbygge vores stærke partnerskaber og ikke mindst have et klart fokus på forebyggelse og bæredygtighed.”

Solvens og udlodning

Alm. Brand Group havde ved udgangen af 3. kvartal 2022 en solvensdækning på 199%, heri inkluderet midler til de resterende restruktureringsomkostninger relateret til integrationen af Codan. Alm. Brand Group sigter mod at have en solvensdækning på 170% fremadrettet og vil under hensyntagen hertil kunne udlodde en høj andel af den fremtidige indtjening til sine aktionærer. Alm. Brand Group ændrer derfor sin udlodningspolitik til en pay-out ratio på minimum 80% og forventer, at udlodningen i de kommende år vil ske i en kombination af udbyttebetaling og aktietilbagekøb.

Dagens præsentation er tilgængelig på investorrelations.almbrand.dk. Kapitalmarkedsmødet vil blive webcastet live klokken 10.00-12.00 GMT og vil efterfølgende ligeledes være tilgængelig her.

Kontakt

Eventuelle henvendelser vedrørende denne selskabsmeddelelse bedes rettet til:

Investorer og aktieanalytikere:

Head of Investor Relations                Senior Investor Relations Officer
Mads Thinggaard                 Mikael Bo Larsen
mobil nr. 20 25 54 69                mobil nr. 51 43 80 02

Presse:

Chef for Kommunikation & Bæredygtighed
Emilie Wedell-Wedellsborg
mobil nr. 20 32 65 30

Vedhæftet fil

For at se dette indhold fra www.globenewswire.com, så skal du give din accept på toppen af denne side.
For at se dette indhold fra ml-eu.globenewswire.com, så skal du give din accept på toppen af denne side.

Information om GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg pressemeddelelser fra GlobeNewswire by notified

Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.

Flere pressemeddelelser fra GlobeNewswire by notified

798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release

BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab23.2.2024 23:35:31 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) announced today that the board decided to grant 418,646 restricted stock units to members of management and employees of the company as well as the company's subsidiaries and 316,899 warrants to employees of the company and the company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of executive management will, with the exception of deferred annual cash bonus, be subject to forward looking performance criteria and consequently represent the maximum opportunity available if the performance targets have been significantly exceeded. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,013. The restricted stock units will vest on the first ban

Karate Combat 46 to enhance Dubai’s standing as a leading sports tourism destination23.2.2024 20:00:38 CET | Press release

KC46 will be held on Saturday 20 April First professional sports league gamified by a blockchain access token DUBAI, United Arab Emirates, Feb. 23, 2024 (GLOBE NEWSWIRE) -- Karate Combat, the world’s premier full-contact professional striking league, has partnered with Dubai Department of Economy and Tourism (DET) and Dubai Sports Council (DSC) to bring Karate Combat 46 (KC46) to the emirate this spring. Expected to be the league’s biggest event to date, KC46 is collaborating with TOKEN2049 for a Saturday 20 April event. As part of the collaboration KC46 will be part of the official programme of TOKEN2049 Week Dubai, giving conference attendees the opportunity to witness one of the world’s most innovative sports leagues through special tickets and the opportunity to meet event ambassadors at the conference. KC46 will be announced by UFC Hall of Famers Georges St-Pierre (GSP) and Bas Rutten, alongside Mike Majlak, author and co-host of the Impaulsive podcast. Karate Combat is the first

HiddenA line styled icon from Orion Icon Library.Eye